Live Breaking News & Updates on Myrisk Hereditary Cancer Test

Stay updated with breaking news from Myrisk hereditary cancer test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Myriad Genetics (NASDAQ:MYGN) Issues FY 2023 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN – Get Free Report) issued an update on its FY 2023 earnings guidance on Thursday morning. The company provided EPS guidance of -0.330–0.280 for the period, compared to the consensus EPS estimate of -0.300. The company issued revenue guidance of $747.0 million-$753.0 million, compared to the consensus revenue estimate of $750.9 million. […] ....

United States , Piper Sandler , Richard Bryan Riggsbee , Jpmorgan Chase Co , Lazard Asset Management , Wolfe Research , Us Bancorp , Ameritas Investment Partners Inc , Genetics Inc , Myriad Genetics , Get Free Report , Bryan Riggsbee , Asset Management , Point Capital Management , Investment Partners , Financial Advisors , Myrisk Hereditary Cancer Test , Germline Companion Diagnostic Test , Companion Diagnostic Test , Myriad Genetics Daily , Nasdaq Mygn ,